NEW YORK (GenomeWeb) – BioView announced on Wednesday that the US Food and Drug Administration has cleared for marketing the firm's Duet System to detect rearrangements involving the ALK gene in non-small cell lung cancer samples.

Specifically, the system has been cleared for the qualitative detection of ALK rearrangements via fluorescence in situ hybridization in formalin-fixed paraffin-embedded NSCLC tissue specimens that are probed with the Abbott Vysis ALK Break Apart FISH Probe Kit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.